738 reports of this reaction
3.0% of all CEFUROXIME reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for CEFUROXIME, manufactured by Hikma Pharmaceuticals USA Inc.. There are 738 FDA adverse event reports linking CEFUROXIME to DYSPNOEA. This represents approximately 3.0% of all 25,003 adverse event reports for this drug.
Patients taking CEFUROXIME who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for CEFUROXIME, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for CEFUROXIME:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 738 FDA reports for CEFUROXIME. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.0% of all adverse event reports for CEFUROXIME, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking CEFUROXIME, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.